EMA Authorised: Phesgo (pertuzumab;trastuzumab) — Roche Registration GmbH

View source ↗

Summary

The European Medicines Agency has authorised Phesgo, a fixed-dose subcutaneous combination of pertuzumab and trastuzumab, for breast cancer treatment with Roche…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Roche Registration GmbH. Decision date: 22/09/2025